ID   MDA-MB-453 Ad15
AC   CVCL_ZZ23
DR   cancercelllines; CVCL_ZZ23
DR   Wikidata; Q102114522
RX   PubMed=9815641;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: Caucasian.
CC   Doubling time: 120.5 hours (PubMed=9815641).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Gln868His (c.2604G>T); Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Trp638Ter (c.1913G>A); ClinVar=VCV000599651; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu307Lys (c.919G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Ex10-11del; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pericardial effusion; UBERON=UBERON_0002409.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0418 ! MDA-MB-453
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 7
//
RX   PubMed=9815641;
RA   Wosikowski K., Schuurhuis D., Kops G.J.P.L., Saceda M., Bates S.E.;
RT   "Altered gene expression in drug-resistant human breast cancer
RT   cells.";
RL   Clin. Cancer Res. 3:2405-2414(1997).
//